Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) EBIT (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of EBIT data on record, last reported at $82.0 million in Q4 2025.

  • For Q4 2025, EBIT rose 321.23% year-over-year to $82.0 million; the TTM value through Dec 2025 reached $59.6 million, changed N/A, while the annual FY2025 figure was $45.1 million, 117.55% up from the prior year.
  • EBIT reached $82.0 million in Q4 2025 per CAI's latest filing, up from $32.6 million in the prior quarter.
  • Across five years, EBIT topped out at $82.0 million in Q4 2025 and bottomed at -$67.0 million in Q2 2024.